Foreign Pharmas Seek To Fill Japan Vacuum For Antibody Drugs
This article was originally published in PharmAsia News
Executive Summary
The lack of antibody drugs marketed by Japanese drug makers is leading foreign pharmas to put their own versions on the market in Japan. Novartis AG is expected to be the first foreign firm to enter the market by the end of the year, with its Xolair (omalizumab) for treating asthma. Companies expected to follow Novartis to the market soon after include Bristol-Myers Squibb and Merck Serono International with their Erbitux (cerbitux) colon cancer drug. Other firms are holding clinical trials in Japan for drug candidates. (Click here for more - a subscription may be required
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.